Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eagle Pharmaceuticals Receives Additional FDA Questions Regarding Vasopressin; Court Date Set for July 7, 2021 in Vasopressin Trial","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"February 2021","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eagle Pharmaceuticals Wins Vasopressin Patent Trial","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"August 2021","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Endo International","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Endo Comments on Non-Infringement Ruling in VASOSTRICT\u00ae Patent Litigation","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"IRELAND","productType":"Peptide","productStatus":"Approved","date":"August 2021","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eagle Pharmaceuticals Receives FDA Approval for Vasopressin","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"December 2021","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"Par Pharmaceutical","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eagle Pharmaceuticals Reports that Par Has Unilaterally Withdrawn Attempt to Halt Launch of Vasopressin","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"December 2021","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Eagle Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eagle Pharmaceuticals Receives 180 Days of Marketing Exclusivity for Recently Approved Vasopressin","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"December 2021","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Dr. Reddy's Laboratories","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Dr. Reddy's Laboratories Announces the Launch of Its Authorized Generic Version of VASOSTRICT\u00ae (vasopressin injection, USP) Vials in the U.S. Market","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Peptide","productStatus":"Approved","date":"February 2022","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Amneal Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amneal Launches 4 New Generic Products, Including Vasopressin Single-dose","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Peptide","productStatus":"Approved","date":"August 2022","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Aurobindo Pharma Limited","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Aurobindo Pharma Arm Gets Final US FDA Nod for Vasopressin injection","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"INDIA","productType":"Peptide","productStatus":"Approved","date":"August 2022","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved"},{"orgOrder":0,"company":"Fresenius Kabi USA, LLC","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Fresenius Kabi Launches Vasopressin Injection, USP Expanding U.S. Critical Care Portfolio","therapeuticArea":"Cardiology\/Vascular Diseases","highestDevelopmentStatus":"Approved","country":"AUSTRIA","productType":"Peptide","productStatus":"Approved","date":"June 2023","url1":"","url2":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals for Arginine Vasopressin

    Menu

    Arginine Vasopressin

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PRICE INFORMATION

    DOSSIERs // Finished Dosage Forms

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS

    ANALYTICAL SOLUTION(s)

    DIGITAL CONTENT

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Dr. Reddy's Laboratories

              Contact Supplier
              • Development Update
              Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.
              Contact Supplier Contact Supplier
              Flag India
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Dr. Reddy's Laboratories Announces the Launch of Its Authorized Generic Version of VASOSTRICT® (vasopressin injection, USP) Vials in the U.S. Market

              Details:

              The launch of authorized generic version of Par Pharmaceutical’s VASOSTRICT® (vasopressin injection, USP) Vials in the U.S. Market was approved by the U.S. Food and Drug Administration (USFDA).

              Lead Product(s): Arginine Vasopressin

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: Vasopressin-Generic

              Highest Development Status: Approved Product Type: Peptide

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 09, 2022

              Dr Reddy Company Banner

              CPhI North America

              Attending

              envelop Contact Supplier

              Fresenius Kabi USA, LLC

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Austria
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Fresenius Kabi Launches Vasopressin Injection, USP Expanding U.S. Critical Care Portfolio

              Details:

              Vasopressin injection is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines and Vasostrict is a RFLD.

              Lead Product(s): Arginine Vasopressin

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: Vasostrict-Generic

              Highest Development Status: Approved Product Type: Peptide

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 14, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Aurobindo Pharma Limited

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag India
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Aurobindo Pharma Arm Gets Final US FDA Nod for Vasopressin injection

              Details:

              Vasopressin Injection is indicated to increase blood pressure in adults with vasodilatory shocks, such as due to post-cardiotomy or sepsis, and remain hypotensive despite fluids and catecholamines.

              Lead Product(s): Arginine Vasopressin

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: Vasopressin-Generic

              Highest Development Status: Approved Product Type: Peptide

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 16, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Amneal Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Amneal Launches 4 New Generic Products, Including Vasopressin Single-dose

              Details:

              Vasopressin injection 1mL is a generic version of the antidiuretic hormone Vasostrict® is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines.

              Lead Product(s): Arginine Vasopressin

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: Vasopressin-Generic

              Highest Development Status: Approved Product Type: Peptide

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 11, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Eagle Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Eagle Pharmaceuticals Receives 180 Days of Marketing Exclusivity for Recently Approved Vasopressin

              Details:

              In August, the U.S. District Court for the District of Delaware held that Eagle’s proposed vasopressin product does not infringe any of the patents Par Pharmaceutical, Inc. et al. asserted against the Company.

              Lead Product(s): Arginine Vasopressin

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: Vasopressin-Generic

              Highest Development Status: Approved Product Type: Peptide

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable December 29, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Eagle Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Eagle Pharmaceuticals Reports that Par Has Unilaterally Withdrawn Attempt to Halt Launch of Vasopressin

              Details:

              The U.S. District Court for the District of Delaware issue a temporary restraining order and preliminary injunction preventing the launch of Eagle’s recently approved vasopressin product.

              Lead Product(s): Arginine Vasopressin

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

              Highest Development Status: Approved Product Type: Peptide

              Partner/Sponsor/Collaborator: Par Pharmaceutical

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable December 29, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Eagle Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Eagle Pharmaceuticals Receives FDA Approval for Vasopressin

              Details:

              This approval follows the recent U.S. District Court for the District of Delaware decision holding that Eagle’s proposed vasopressin product does not infringe any of the patents Par Pharmaceutical, Inc. et al. asserted against the Company.

              Lead Product(s): Arginine Vasopressin

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: Vasopressin-Generic

              Highest Development Status: Approved Product Type: Peptide

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable December 15, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Eagle Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Eagle Pharmaceuticals Wins Vasopressin Patent Trial

              Details:

              Eagle is first to file an Abbreviated New Drug Application (“ANDA”) referencing Vasostrict®, which had total U.S. sales of $786 million in 2020.

              Lead Product(s): Arginine Vasopressin

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

              Highest Development Status: Approved Product Type: Peptide

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 31, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Endo International

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Ireland
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Endo Comments on Non-Infringement Ruling in VASOSTRICT® Patent Litigation

              Details:

              United States District Court for the District of Delaware's non-infringement found non-infringement of Endo's patents by Eagle's proposed ANDA for Par Sterile Products, LLC's VASOSTRICT® product, it did not rule on the patents' validity.

              Lead Product(s): Arginine Vasopressin

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: Vasostrict

              Highest Development Status: Approved Product Type: Peptide

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 31, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Eagle Pharmaceuticals

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Eagle Pharmaceuticals Receives Additional FDA Questions Regarding Vasopressin; Court Date Set for July 7, 2021 in Vasopressin Trial

              Details:

              The U.S. FDA has issued a complete response letter for Eagle's Abbreviated New Drug Application for vasopressin. Eagle has now had two conversations with FDA regarding the CRL and will have an additional meeting with FDA within 30 days.

              Lead Product(s): Arginine Vasopressin

              Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed

              Highest Development Status: Approved Product Type: Peptide

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 02, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Phyton is a World Leader in Plant Cell Fermentation Technology and Commercial Manufacturing.
              Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.
              Post Enquiry
              POST ENQUIRY